SR One related stories
All articles and analysis
NeuroTherapeutics Pharma Raises $43 MillionNeuroTherapeutics Pharma Inc., a Chicago-based developer of therapies for central nervous system (CNS) disorders, has raised $43 million in Series B funding. Fidelity Biosciences, MPM Capital and S.R. One Ltd. co-led the round, and were joined by Pfizer and return backers Novo Ventures and Thomas McNerney & Partners.
- Executive moves, week of May 3, 2010
Personnel changes SR One, Spark, Centerview and other PE and VC firms
- Week in deals, June 22, 2009
Summary of tech companies and other businesses that raised financing in North America in the past week
- Week in deals, June 15, 2009
Summary of tech companies and other businesses that raised financing in North America in the past week
- Aileron raises $40M
Drug developer focuses on treatments for cancer, and immune, metabolic and infectious diseases.
- Alios BioPharma Raises $32 Million
Alios BioPharma Inc., a South San Francisco-based drug startup, has closed its Series A round with a total of $32 million. This includes a first close from last December, from firms like Novo AS, Novartis BioVentures and Roche Finance Ltd. The second close came from SR One Ltd., the corporate venture arm of GlaxoSmithKline. The company says that it plans to “treat diseases in virology by activating pathways in the innate immune system.”
- peHUB Wire: Monday, June 8, 2009
Random Ramblings
- peHUB Wire: Monday, June 8, 2009
Random Ramblings
- peHUB Wire: Tuesday, June 2, 2009
Random Ramblings